ABDXF: AI 评分 54/100 — AI 分析 (4月 2026)

Abingdon Health Plc develops, manufactures, and distributes diagnostic devices globally, including rapid antibody and antigen tests. The company also offers contract manufacturing and consultancy services to businesses in the healthcare technology sector.

Key Facts: AI Score: 54/100 Sector: Healthcare

公司概况

概要：

Abingdon Health Plc specializes in diagnostic device development, manufacturing, and distribution, focusing on rapid testing solutions like COVID-19 tests and nucleic acid lateral flow immunoassays. The company serves a global market, offering both product sales and contract services within the medical diagnostics industry.

ABDXF是做什么的？

Abingdon Health Plc, incorporated in 2008 and headquartered in York, United Kingdom, operates within the medical diagnostics industry, focusing on the development, manufacture, and distribution of a range of diagnostic devices. The company's product portfolio includes the AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test, as well as nucleic acid lateral flow immunoassays, PCRD and PCRD FLEX for rapid readouts post isothermal amplification, the Abingdon Simply Test range of self-tests, and the 2019-nCoV Antigen Test for qualitative detection of antigens to SARS-CoV-2. Abingdon Health also offers AppDx, a customizable image capturing technology that transforms smartphones into lateral-flow readers. Beyond its proprietary products, Abingdon Health provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. The company extends its expertise through consultancy services to businesses operating in the healthcare technology sector. Abingdon Health has a collaboration and co-marketing agreement with Abcam plc, enhancing its market reach and product development capabilities.

ABDXF的投资论点是什么？

Abingdon Health Plc presents a focused play on the diagnostics market, particularly in rapid testing solutions. With a market capitalization of $0.01 billion, the company's negative P/E ratio of -9.12 reflects current challenges in achieving profitability, despite a gross margin of 37.1%. Key value drivers include expansion of its contract manufacturing services and successful commercialization of its AppDx technology. Growth catalysts include potential partnerships and increased demand for rapid diagnostic solutions. Potential risks include competition from established players and the need to achieve sustainable profitability. Investors should monitor the company's ability to leverage its existing product portfolio and strategic collaborations to drive revenue growth and improve financial performance.

ABDXF在哪个行业运营？

Abingdon Health Plc operates in the medical diagnostics industry, a sector characterized by continuous innovation and increasing demand for rapid and accurate testing solutions. The market is driven by factors such as the growing prevalence of infectious diseases, the increasing adoption of point-of-care diagnostics, and advancements in biotechnology. Competitors include companies like CRPOF (CareRx Corporation), EIGRQ (Eurofins Scientific SE), MNNDF (MIND Technology, Inc.), NOXOF (Noxopharm Ltd), and PXXLF (Pro-Dex, Inc.). Abingdon Health's focus on lateral flow technology positions it to capitalize on the demand for rapid and cost-effective diagnostic tests.

Medical - Diagnostics & Research

Healthcare

ABDXF有哪些增长机遇？

Expansion of Contract Manufacturing Services: Abingdon Health can leverage its manufacturing capabilities to secure more contract manufacturing agreements with other healthcare companies. The global contract manufacturing market for medical devices is projected to reach $108.1 billion by 2027, presenting a significant opportunity for Abingdon Health to increase its revenue and profitability. Timeline: Ongoing.
Commercialization of AppDx Technology: The AppDx technology, which transforms smartphones into lateral-flow readers, has the potential to disrupt the point-of-care diagnostics market. By partnering with healthcare providers and diagnostic test developers, Abingdon Health can drive adoption of AppDx and generate recurring revenue through software licenses and data analytics services. Timeline: Ongoing.
Strategic Partnerships and Collaborations: Abingdon Health can pursue strategic partnerships and collaborations with other companies in the healthcare industry to expand its product portfolio and market reach. The collaboration with Abcam plc is a positive example, and further partnerships could accelerate growth. Timeline: Ongoing.
Development of New Diagnostic Tests: Abingdon Health can invest in the development of new diagnostic tests for various diseases and conditions. The global diagnostics market is expected to reach $137.7 billion by 2028, driven by advancements in technology and increasing demand for personalized medicine. Timeline: Ongoing.
Geographic Expansion: Abingdon Health can expand its operations into new geographic markets, particularly in developing countries where there is a growing need for affordable and accessible diagnostic tests. The company can leverage its existing product portfolio and manufacturing capabilities to establish a presence in these markets. Timeline: Ongoing.

Market capitalization of $0.01 billion indicates a small-cap company with potential for growth but also higher risk.
Negative P/E ratio of -9.12 reflects current unprofitability, requiring careful monitoring of future earnings.
Gross margin of 37.1% demonstrates the potential for profitability if operational efficiencies are improved.
Beta of 0.18 suggests low volatility compared to the overall market, indicating a relatively stable stock.
Collaboration with Abcam plc provides access to a broader market and enhances product development capabilities.

ABDXF提供哪些产品和服务？

Develops rapid diagnostic tests for infectious diseases.
Manufactures lateral flow immunoassays.
Offers COVID-19 antibody and antigen tests.
Provides contract manufacturing services for diagnostic devices.
Offers a smartphone-based lateral flow reader technology (AppDx).
Provides consultancy services to healthcare technology businesses.

ABDXF如何赚钱？

Sales of rapid diagnostic tests (e.g., COVID-19 tests).
Contract manufacturing for other diagnostic companies.
Licensing and sales of AppDx technology.
Consultancy services for healthcare businesses.

Healthcare providers (hospitals, clinics).
Diagnostic test developers.
Pharmaceutical companies.
Research institutions.

Proprietary lateral flow technology.
Established manufacturing capabilities.
Strategic collaboration with Abcam plc.
Expertise in diagnostic test development.

什么因素可能推动ABDXF股价上涨？

Upcoming: Potential new contract manufacturing agreements.
Ongoing: Commercialization of AppDx technology.
Ongoing: Expansion of diagnostic test portfolio.
Ongoing: Strategic partnerships and collaborations.
Ongoing: Geographic expansion into new markets.

ABDXF的主要风险是什么？

Potential: Intense competition from established diagnostic companies.
Potential: Decline in demand for COVID-19 testing.
Potential: Regulatory changes in the healthcare industry.
Potential: Economic downturn affecting healthcare spending.
Ongoing: Negative P/E ratio indicating current unprofitability.

ABDXF的核心优势是什么？

Established expertise in lateral flow technology.
Manufacturing capabilities for diagnostic devices.
Collaboration with Abcam plc.
Diverse product portfolio including COVID-19 tests.

ABDXF的劣势是什么？

Negative P/E ratio indicating current unprofitability.
Small market capitalization.
Dependence on COVID-19 testing market.
Limited brand recognition compared to larger competitors.

ABDXF有哪些机遇？

Expansion of contract manufacturing services.
Commercialization of AppDx technology.
Development of new diagnostic tests.
Geographic expansion into developing markets.

ABDXF面临哪些威胁？

Intense competition from established diagnostic companies.
Decline in demand for COVID-19 testing.
Regulatory changes in the healthcare industry.
Economic downturn affecting healthcare spending.

ABDXF的竞争对手是谁？

CareRx Corporation — Provides pharmacy services to seniors. — (CRPOF)
Eurofins Scientific SE — Offers testing and laboratory services. — (EIGRQ)
MIND Technology, Inc. — Provides technology for the energy sector. — (MNNDF)
Noxopharm Ltd — Focuses on cancer drug development. — (NOXOF)
Pro-Dex, Inc. — Manufactures powered surgical instruments. — (PXXLF)

Key Metrics

MoonshotScore: 54/100

Company Profile

CEO: Christopher William Hand
Headquarters: York, GB
Employees: 113
Founded: 2022

AI Insight

AI analysis pending for ABDXF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Abingdon Health Plc do?

Abingdon Health Plc is a medical diagnostics company that develops, manufactures, and distributes a range of diagnostic devices, including rapid antibody and antigen tests for infectious diseases like COVID-19. The company also offers contract manufacturing services for other diagnostic companies and has developed AppDx, a smartphone-based lateral flow reader technology. Abingdon Health serves healthcare providers, diagnostic test developers, and pharmaceutical companies worldwide.

What do analysts say about ABDXF stock?

AI analysis is currently pending for ABDXF. However, given the company's small market capitalization and negative P/E ratio, analysts are likely to focus on its ability to achieve profitability and generate sustainable revenue growth. Key valuation metrics to consider include revenue growth rate, gross margin, and operating expenses. Investors should monitor the company's progress in commercializing its AppDx technology and securing new contract manufacturing agreements.

What are the main risks for ABDXF?

The main risks for Abingdon Health Plc include intense competition from larger and more established diagnostic companies, a potential decline in demand for COVID-19 testing, and regulatory changes in the healthcare industry. The company's negative P/E ratio also indicates a risk of continued unprofitability. Additionally, as an OTC-listed stock, ABDXF is subject to higher liquidity risk and potential price volatility compared to stocks listed on major exchanges.